All In MedTech

FDA Clearance Tracker · P990040-S009

TRUFILL N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 25, 2010 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 25, 2010

Approved

Time to decision

178 days

Received Aug 31, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P990040-S009
Device name
TRUFILL N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM
Applicant location
Miami, FL
Received
Aug 31, 2009
Decided
Feb 25, 2010
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990040

Device type

Device class
Class III

Every decision under product code KGG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MANUFACTURING SITES LOCATED AT CODMAN & SHURTLEFF, INC. IN RAYNHAM, MASSACHUSETTS AND BRIDGEWATER, MASSACHUSETTS.

Source documents

Other decisions for Cerenovus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.